代谢酶突变或可帮助脑部肿瘤躲避免疫治疗

in cancer：Their role in tumor progression and response to therapy[ J] • Curr Mol Med ，2012,12( 1) :27 -33.28
Lu Y,Roy S,Nuovo G ,et al. Anti - microRNA -222(anti -miR -222) and - 181 B suppress growth of tamoxifen - resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signalf J ]. Biol Chem ,2011,286 (49) ：42292 -42302.
29 Sachdeva M,Mo YY. MicroRNA - 145 suppresses cell in­
vasion and metastasis by directly targeting mucin 1 [ J ]. Cancer R es,2010,70( 1) ：378 -387.
30 Shi W ,Gerster K,Alajez NM,et al. MicroRNA -301 medi­
ates proliferation and invasion in human breast cancer[ J ]. Cancer R es,2011,71 (8) ：2926 -2937.31
Ward A,Shukla K,Balwierz A ,et al. MicroRNA -519a is a novel oncomir conferring tamoxifen resistance by targe­ting a network of tumour - suppressor genes in ER + breast can cer[J]. Pathol,2014,233(4) ：368 -379.32 Hoppe R,Achinger - Kawecka J , Winter S ,et al. Increased
expression of miR — 126 and miR — 10a predict prolonged relapse - free time of primary oestrogen receptor - positive breast cancer following tamoxifen treatment [ J ]. Eur J
• 164 •
Cancer,2013,49(17) ：3598 -3608.
33 Zhang W ,Xu J,Shi Y ,et al. The novel role of miRNAs for
tamoxifen resistance in human breast c a n c e r[J]. Cell Mol Life Sci ,2015,72(13) ：2575 - 2584.
34 Li CH ,Chen Y. Targeting long non - coding RNAs in canc­
ers ：Progress and prospects [ J ]. Int J Biochem Cell Biol, 2013,45(8)： 1895 -1910.
35
Hayes EL, Lewis - Wambi JS. Mechanisms of endocrine re­sistance in breast cancer ： An overview of the proposed roles of noncoding RNA[ J ]. Breast Cancer R es,2015,5 ( 17)： 40.
36 Su X,Malouf GG,Chen Y ,et al. Comprehensive analysis of
long non - coding RNAs in human breast cancer clinical subtypes[J]. O ncotarget,2014,5(20) ：9864 -9876.37 Xue X, Yang YA,Zhang A ,e t al. LncRNA HOTAIR en- hanceser signaling and confers tamoxifen resistance in breast can cer[J]. Oncogene,2016,35(21) ,2746 -2755.38 Xing Z,Lin A ,Li C ,et al. LncRNA directs cooperative epi­genetic regulation downstream of chemokine signals [ J ]. C e ll,2014,159(5)：1110-1125.
(收稿:2016-12-07)
实用肿瘤学杂志2017年第31卷第2期总第148期
•肿瘤快讯•
代谢酶突变或可f 助脑都肿瘤躲避兔痰治磅
有关研究人员研究了异柠檬酸脱氢酶（IDH )发生突变是否会帮助肿瘤抵抗免疫治疗。

研究人员在人类星形肢质细胞和神经肢质瘤小鼠模型上发现，IDH 发生突变会通过降低对T 细胞的招募抑制T 细胞在肿瘤部位的聚集损伤肿瘤微环境中的免疫应答。

因此ID H 突变或 可帮助神经肢质瘤躲避依赖免疫系统激活的抗肿瘤靶向治疗。

重要的是，研究人员在神经肢 质瘤小鼠模型上观察到利用突变IDH 1的一种特异性抑制剂IDH -135可以逆转突变引起的
T 细胞聚集受阻，并且抑制突变的ID H 能够增强以疫苗为基础的免疫治疗方法。

该发现提示
联合疗法或能够对抗ID H 突变造成的影响，提高神经肢质瘤对免疫治疗的应答情况。

（摘 自：JC I )。